Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2016-000212-16-FI
EUCTR2016-000212-16-FIActive, not recruitingNot Applicable

Hydrocortisone vs. pasireotide in preventing pancreatic fistula and other complications after pancreatic resection - a prospective, randomized, controlled trial

Helsinki University Central Hospital0 sitesStarted: March 30, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Patients undergoing pancreatic resection.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 80
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 44

Exclusion Criteria

  • •- Atrophic pancreas, dilated main pancreatic duct at the site of pancreaticojejunostomy
  • •- Total pancreatectomy
  • •- Allergy to studied medications
  • •- Age < 18 years
  • •- No written consent
  • •- Pancreatic resection not performed, even if planned
  • •- Hard pancreas/dilated main pancreatic duct (only patients undergoing PD)

Investigators

Similar Trials

Completed
Phase 2
Effect of intravenous hydrocortisone in preventing post operative sore throatSore throat.Sore throat (acute) NOS
IRCT201104094005N3Vice chancellor for research,Tabriz University of Medical Sciences60
Active, not recruiting
Phase 4
HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery ComplicationsPancreatic FistulaPancreatic Neoplasms
NCT02775227Helsinki University Central Hospital126
Completed
Phase 2
Prophylactic use of hydrocortisone containing mouthwash in the prevention of mTOR inhibitor-associated stomatitis
JPRN-UMIN000025408Aichi Cnacer Center30
Active, not recruiting
Not Applicable
Effect of Calcipotriol Plus Hydrocortisone Ointment on the HPA Axis and Calcium Metabolism in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous AreasPsoriasis vulgaris on the face and on the intertriginous areas.The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus).In case of baldness or partial baldness, the forehead should be estimated considering standard or previous hairline.Intertriginous areas are defined as: 1) the axillae 2) the genito-femoral and inguinal folds 3) the inframammary folds 4) the intergluteal folds and 5) the scrotum.MedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgaris
EUCTR2007-005501-22-DEEO Pharma A/S30
Active, not recruiting
Phase 1
Effect of Calcipotriol Plus Hydrocortisone Ointment on the HPA Axis and Calcium Metabolism in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous AreasPsoriasis vulgaris on the face and on the intertriginous areas. The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldness or partial baldness, the forehead should be estimated considering standard or previous hairline. Intertriginous areas are defined as: 1) the axillae 2) the genito-femoral and inguinal folds 3) the inframammary folds 4) the intergluteal folds and 5) the scrotum.MedDRA version: 9.1 Level: LLT Classification code 10050576 Term: Psoriasis vulgaris
EUCTR2007-005501-22-GBEO Pharmaceuticals Products Ltd. A/S (LEO Pharma A/S)35